House of Lords

Business

Arcturus Therapeutics: Market Skepticism Paints a Zero-Success Picture for Pipeline, But Analysts See Deep Value

Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.

Feb 2, 2026

Business

Autoliv Gains Analyst Favor Amid Auto Sector Affordability Headwinds

Baird raises its price target on Autoliv (ALV), citing resilience in the automotive safety giant's long-term outlook, even as near-term affordability concerns pressure the broader vehicle market.

Feb 2, 2026

Business

Analysts Remain Bullish on Visteon Despite Price Target Trims, Citing Strong Auto Tech Demand

Goldman Sachs and Baird reaffirm positive ratings on automotive technology supplier Visteon (VC), seeing significant upside potential even after modestly lowering price targets, driven by favorable sector outlook and growth in digital cockpit solutions.

Feb 2, 2026

Business

Walmart Expands Global Reach with New Export Program for Marketplace Sellers

Walmart is launching a cross-border shipping initiative early this year, enabling U.S.-based third-party sellers to directly reach consumers in Mexico and Canada, intensifying its e-commerce competition with Amazon.

Feb 2, 2026

Business

Lexeo Therapeutics Faces Market Skepticism Despite Positive PKP2 Gene Therapy Data

H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.

Feb 2, 2026

Business

Goodyear Poised for Growth as Replacement Tire Market Gains Momentum

Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.

Feb 2, 2026

Business

Aptiv Gains Analyst Favor as Strategic Shift Yields 'More Realistic' Growth Outlook

Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.

Feb 2, 2026

Business

Mobileye Eyes 2026 as Pivotal Year Amid Analyst Backing and Strategic Shifts

Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.

Feb 2, 2026

Business

AutoZone Revs Up Expansion Plans as Analysts Debate Outlook Amid Sales Pressure

Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.

Feb 2, 2026

Business

Disney's Sora-Generated Shorts to Debut on Disney+, But Iger Insists Core Slate Unaffected

Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.

Feb 2, 2026

Business

Google Integrates Gemini AI Deeper Into Chrome, Reshaping the Browser Experience

Google is rolling out a significant update to its Chrome browser, embedding advanced Gemini AI capabilities directly into the user interface. The move signals a strategic push to make AI a central, everyday tool for web navigation and tasks.

Feb 2, 2026

Business

Alibaba's Cainiao to Invest $2 Billion in Autonomous Trucking Startup Zelos Technology

Alibaba's logistics arm Cainiao is making a major strategic move into autonomous freight, with a reported $2 billion investment in L4 self-driving truck firm Zelos Technology, signaling a deepening push into AI-driven supply chain solutions.

Feb 2, 2026

Business

Cathie Wood Doubles Down on Broadcom, Betting Big on AI and Datacenter Dominance

ARK Invest's Cathie Wood has aggressively added to her position in Broadcom (AVGO) this month, signaling strong conviction in the chipmaker's AI and datacenter prospects despite recent share price weakness, as analysts also turn bullish on the stock's long-term trajectory.

Feb 2, 2026

Business

Grail Seeks FDA Green Light for Pioneering Multi-Cancer Blood Test, Paving Way for Broader Insurance Coverage

The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.

Feb 2, 2026

Business

Analysts Shift Stance: Palantir Gets Bullish Nod While Best Buy Faces Downgrade Pressure

Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.

Feb 2, 2026

Business

Beyond Survival: Eight Trends Redefining Small Business Success in 2026

A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.

Feb 2, 2026

Business

Analysts See Long-Term Promise in Legend Biotech's Carvykti Despite Fourth-Quarter Sales Shortfall

While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.

Feb 2, 2026

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.

Feb 2, 2026

Business

Taysha Gene Therapies Gains Momentum as Wells Fargo Raises Target on Rett Syndrome Program

Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.

Feb 2, 2026

Business

Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny

Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.

Feb 2, 2026